Medtronic, Inc. v. Mirowski Family Ventures, LLC

Medtronic, Inc. v. Mirowski Family Ventures, LLC

Argued November 5, 2013
Decided January 22, 2014
Full case name Medtronic, Inc. v. Mirowski Family Ventures, LLC
Docket nos. 12-1128
Citations

571 U.S. ___ (more)

Prior history Medtronic Inc. v. Bos. Scientific Corp., 695 F.3d 1266 (Fed. Cir. 2012). , vacating and remanding Medtronic, Inc. v. Boston Scientific Corp., 777 F.Supp.2d 750 (D. Del. 2011). Certiorari granted May 20, 2013
Argument Oral argument
Opinion Announcement Opinion announcement
Holding
When a licensee seeks a declaratory judgment against a patentee that its products do not infringe the licensed patent, the patentee bears the burden of persuasion on the issue of infringement.
Court membership
Chief Justice
John G. Roberts
Case opinions
Majority Breyer, joined by unanimous court
Laws applied
28 U.S.C. § 1338 (district court jurisdiction over patents), 28 U.S.C. § 2201 (power to issue declaratory judgment)

Medtronic, Inc. v. Mirowski Family Ventures, LLC is a case of the Supreme Court of the United States that deals with civil procedure, and specifically with the question of the burden of proof required in pursuing declaratory judgments.

Background

In 1991, Medtronic and Mirowski entered into an agreement permitting Medtronic to practice certain Mirowski patents in exchange for royalty payments. In 2007, the parties found themselves in the midst of an "infringement" dispute, and Mirowski gave Medtronic notice that it believed seven new Medtronic products violated various claims contained in two of its patents,[lower-alpha 1] which dealt with cardiac resynchronization therapy,[4] a pacemaker that is used to treat congestive heart failure.[5] Medtronic thought that its products did not infringe Mirowski's patents, either because the products fell outside the scope of the patent claims or because the patents were invalid.

Medtronic brought an action for declaratory judgment in the United States District Court for the District of Delaware, seeking a declaration that its products did not infringe Mirowski's patents and that the patents were invalid.

The courts below

The District Court recognized that Mirowski was the defendant in the action,but it held that Mirowski, "[a]s the part[y] asserting infringement," bore the burden of proving infringement.[6] After a bench trial, the court found that Mirowski had not proved infringement, either directly or under the doctrine of equivalents, and it therefore lost.

On appeal, the United States Court of Appeals for the Federal Circuit held that "when an infringement counterclaim by a patentee is foreclosed by the continued existence of a license, a licensee seeking a declaratory judgment of noninfringement and of no consequent liability under the license bears the burden of persuasion."[7] Therefore, Medtronic, as plaintiff, bore the burden of proof, and the District Court ruling was vacated and remanded.

Because of the importance of burdens of proof in patent litigation, the Supreme Court granted certiorari to hear the appeal.

At the Supreme Court

In a unanimous ruling, the Court reversed the Federal Circuit ruling. Justice Breyer held that, when a licensee seeks a declaratory judgment against a patentee to establish that there is no infringement, the burden of proving infringement remains with the patentee. He stated that "Simple legal logic, resting upon settled case law, strongly supports our conclusion."[8] The case law in question has held that:

  1. Following the traditional rule that the plaintiff has the burden of proof, the "burden of proving infringement generally rests upon the patent[-holder]" seeking to enforce the patent.[9]
  2. "The operation of the Declaratory Judgment Act[10] [is] only procedural,"[11] leaving "substantive rights unchanged."[12]
  3. "The burden of proof is a substantive aspect of a claim."[13]

Breyer also noted that "practical considerations lead to the same conclusion":

“

To shift the burden depending upon the form of the action could create postlitigation uncertainty about the scope of the patent. Suppose the evidence is inconclusive, and an alleged infringer loses his declaratory judgment action because he failed to prove noninfringement. The alleged infringer, or others, might continue to engage in the same allegedly infringing behavior, leaving it to the patentee to bring an infringement action. If the burden shifts, the patentee might lose that action because, the evidence being inconclusive, he failed to prove infringement. So, both sides might lose as to infringement, leaving the infringement question undecided, creating uncertainty among the parties and others who seek to know just what products and processes they are free to use.[8]

 ”

Since the Declaratory Judgment Act does not "extend" the "jurisdiction" of the federal courts,[14] the action is properly characterized as one "arising under an Act of Congress relating to patents."[15][16] It could therefore be raised in place of an infringement suit:

“

The relevant question concerns the nature of the threatened action in the absence of the declaratory judgment suit. Medtronic believes — and seeks to establish in this declaratory judgment suit — that it does not owe royalties because its products are noninfringing. If Medtronic were to act on that belief (by not paying royalties and not bringing a declaratory judgment action), Mirowski could terminate the license and bring an ordinary federal patent law action for infringement.... Consequently this declaratory judgment action, which avoids that threatened action, also "arises under" federal patent law....[16]

 ”

Impact

Medtronic is a consequence of the Court's previous ruling in MedImmune, Inc. v. Genentech, Inc., which cleared the way for declaratory judgments to be sought in patent cases. The question as to who bears the burden of proof in such proceedings was the matter at issue in the present case.[17] One commentator welcomed it, saying, "the straightforward, undiverted analysis of the burden of proof question would be perfect for the section of a civil procedure text on declaratory judgments."[18]

Other commentators pointed out that the case was a reminder that patentees should take great care when corresponding with its licensees, as the former must bear the burden of proving their assertions in any subsequent litigation.[19]

Notes

  1. ↑ United States Reissued Patent Nos. RE 38,119[1] and RE 39,897,[2] both reissues of U.S. Patent No. 4,928,688[3]

References

  1. ↑ "US RE38,119" (PDF). May 20, 2003.
  2. ↑ "US RE39,897" (PDF). October 23, 2007.
  3. ↑ US patent 4928688, Mower, Morton M., "Method and apparatus for treating hemodynamic disfunction", issued May 29, 1990
  4. ↑ "What Is a Cardiac Resynchronization Therapy Device?". Medtronic.
  5. ↑ "U.S. Supreme Court tosses out Medtronic pacemaker patent loss". Reuters. January 22, 2014.
  6. ↑ D. Del., at 766
  7. ↑ Fed. Cir., at 1274
  8. 1 2 S.Ct., III-A
  9. ↑ Imhaeuser v. Buerk, 101 U.S. 647 (1880)
  10. ↑ 28 U.S.C. § 2201
  11. ↑ Aetna Life Ins. Co. v. Haworth, 300 U.S. 227 (1937)
  12. ↑ Beacon Theatres, Inc. v. Westover, 359 U.S. 500 (1959)
  13. ↑ Raleigh v. Illinois Dept. of Revenue, 530 U.S. 15 (2000)
  14. ↑ Skelly Oil Co. v. Phillips Petroleum Co., 339 U.S. 667 (1950)
  15. ↑ 28 U.S.C. § 1338
  16. 1 2 S.Ct., II
  17. ↑ Ronald Mann (November 8, 2013). "Argument analysis: Justices worry that Federal Circuit has thumb on the scale for patent-holders". SCOTUSblog.
  18. ↑ Ronald Mann (January 23, 2014). "Opinion analysis: Justices unimpressed with Federal Circuit’s mastery of federal procedure curriculum". SCOTUSblog.
  19. ↑ "Supreme Court Delivers a Jolt to Patentees in Medtronic". Bracewell & Giuliani LLP. January 23, 2014.
This article is issued from Wikipedia - version of the Wednesday, February 24, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.